After Omeros (OMER) announced that narsoplimab, its drug candidate for the treatment of primary IgA nephropathy, or IgAN, did not meet the primary endpoint in the Phase 3 ARTEMIS-IGAN study and the company decided to discontinue the trial and not further pursue the IgAN indication, H.C. Wainwright analyst Arthur He says the news is positive for Calliditas Therapeutics (CALT) as it alleviates near-term competition in the IgAN space and “should bode well for Tarpeyo’s growth.” The firm maintains a Buy rating and 12-month price target of $50 on Calliditas shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CALT:
- Calliditas Therapeutics announces COMP opinion on setanaxib
- Calliditas Therapeutics presents Phase 3 NefIgArd study data
- Calliditas Therapeutics partner submits request to MHRA to convert Kinpeygo CMA
- Calliditas Therapeutics presents data from the NefIgArd Phase 3 trial
- Stada, Calliditas submit EMA request to convert Kinpeygo marketing authorization
